When was Zai Lab founded?

Zai Lab was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Where is Zai Lab located?

Zai Lab is headquartered in Shanghai, China.

How many employees does Zai Lab have?

As of Aug 31, 2026, the latest employee count at Zai Lab is 536.

Is Zai Lab a funded company?

Zai Lab is a funded company, having raised a total of $160M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Aug 27, 2014.

When was the latest funding round of Zai Lab?

Zai Lab's latest funding was a $***** Series C round on Jun 30, 2017, with participation from 4 investors.

What is the annual revenue of Zai Lab?

Annual revenue of Zai Lab is between $100M and $500M as on Dec 31, 2025

Where does Zai Lab rank among its competitors?

Zai Lab ranks 34th amongst 3486 active competitors, of which 1167 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Zai Lab?

Zai Lab's top competitors include Jazz Pharmaceuticals, BeiGene and argenx. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Zai Lab - 2026 Company Profile, Team, Funding, Competitors & Financials

Zai Lab is a public company based in Shanghai (China), founded in 2013 by Samantha Du. It operates as a Developer of drugs for anti-cancer and anti-inflammatory diseases. Zai Lab has raised $160M in funding. The company has 3486 active competitors, including 1167 funded and 823 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and argenx.

Company Details

Developer of drugs for anti-cancer and anti-inflammatory diseases. It has developed antibody-based therapies for hepatocellular carcinoma and lung cancer. It also develops products to treat asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, and graft versus host disease.

Key Metrics

Founded Year

2013

Location

Shanghai, China

Stage

Public

Total Funding

$160M in 3 rounds

Latest Funding Round

Series C, Jun 30, 2017, $*****

Investors

Rock Springs Capital & 10 more

Ranked

34^th among 3486 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2025

Employee Count

536 as on Aug 31, 2026

Investment & Acquisitions

Caidya

Similar Companies

Jazz Pharmaceuticals & 3196 more

Exit Details

Public

View Zai Lab's full profile

Zai Lab is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
ZAI LAB LTD CIN: 1704292 , United States, Active	Apr 20, 2017	$100M - $500M (As on Dec 31, 2025)	-	-

Zai Lab got listed on Sep 20, 2017.

Click here to take a look at Zai Lab's IPO in detail

Zai Lab has raised a total funding of $160M over 3 rounds. Its first funding round was on Aug 27, 2014. Its latest funding round was a Series C round on Jun 30, 2017 for $*****. 4 investors participated in its latest round. Zai Lab has 11 institutional investors.

Here is the list of recent funding rounds of Zai Lab:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 30, 2017	1002420	Series C	7413640	1289505	8262527	3016321
Jan 08, 2016	3695064	Series B	7505774	1200817	9813387	Orbimed & 4 more
Aug 27, 2014	2715151	Series A	8004348	3322908	4000469	Qiming Venture Partners & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Zai Lab's funding rounds and investors

The founders of Zai Lab is Samantha Du.

Here are the details of Zai Lab's key team members:

Samantha Du: Co-Founder & CEO of Zai Lab and founder of 1 other company.
Contact Info: 1 email address

View details of Zai Lab's Founder profiles and Board Members

Zai Lab's employee count trend

Zai Lab has 536 employees as of Aug 26. Here is Zai Lab's employee count trend over the years:

Uncover Zai Lab's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Zai Lab include Jazz Pharmaceuticals, BeiGene and argenx. Here is the list of Top 10 competitors of Zai Lab, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
7th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
34th	Zai Lab 2013, Shanghai (China), Public	Developer of drugs for anti-cancer and anti-inflammatory diseases	$160M	Rock Springs Capital, Kleiner Perkins & 9 others	67/100